Avid Bioservices, Inc. (CDMO)
Stock Price:
$8.20 USD
0.05 (0.61%)
Updated Oct 23, 2020 4:00 PM EDT - Market closed
Key Info
| Market Cap |
464.14M |
| Revenue (ttm) |
69.84M |
| Net Income (ttm) |
-2.57M |
| Shares Out |
56.60M |
| EPS (ttm) |
-0.13 |
| PE Ratio |
n/a |
| Forward PE |
78.74 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Oct 23, 2020 |
| Last Price |
$8.20 |
| Previous Close |
$8.15 |
| Change ($) |
0.05 |
| Change (%) |
0.61% |
| Day's Open |
8.18 |
| Day's Range |
7.96 - 8.26 |
| Day's Volume |
139,099 |
| 52-Week Range |
3.02 - 9.10 |
More Stats
| Market Cap |
464.14M |
| Enterprise Value |
457.76M |
| Earnings Date (est) |
Dec 14, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
56.60M |
| Float |
56.16M |
| EPS (basic) |
-0.13 |
| EPS (diluted) |
-0.13 |
| FCF / Share |
0.03 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
0.38% |
| Payout Ratio |
n/a |
| Shares Short |
1.94M |
| Short Ratio |
4.05 |
| Short % of Float |
3.45% |
| Beta |
2.26 |
| PE Ratio |
n/a |
| Forward PE |
78.74 |
| P/FCF Ratio |
263.87 |
| PS Ratio |
6.65 |
| PB Ratio |
9.91 |
| Revenue |
69.84M |
| Operating Income |
-2.85M |
| Net Income |
-2.57M |
| Free Cash Flow |
1.76M |
| Net Cash |
6.38M |
| Net Cash / Share |
0.11 |
| Gross Margin |
5.63% |
| Operating Margin |
-4.08% |
| Profit Margin |
-11.40% |
| FCF Margin |
2.52% |
| ROA |
-1.50% |
| ROE |
-5.35% |
| ROIC |
-4.40% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (2)
| Buy |
2 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$11.00*
(34.15% upside)
Low
11.0
Current: $8.20
High
11.0
Target: 11.00
*Average 12-month price target from 2 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|
| Revenue | 59.70 | 53.60 | 53.62 | 57.63 | 44.36 | 26.78 | 22.40 | 21.68 | 15.23 | 13.49 |
| Revenue Growth | 11.38% | -0.03% | -6.96% | 29.92% | 65.63% | 19.55% | 3.31% | 42.34% | 12.9% | - |
| Gross Profit | 3.93 | 7.22 | -2.92 | 19.37 | 21.39 | 11.19 | 9.29 | 9.09 | 5.08 | 6.20 |
| Operating Income | -10.94 | -5.62 | -20.64 | 1.29 | 3.49 | -50.50 | -35.71 | -28.35 | -42.07 | -34.69 |
| Net Income | -10.47 | -4.22 | -21.81 | -28.16 | -55.65 | -50.36 | -35.36 | -29.78 | -42.12 | -34.15 |
| Shares Outstanding | 56.33 | 55.98 | 47.06 | 37.11 | 30.90 | 26.08 | 23.08 | 17.20 | 11.94 | 8.70 |
| Earnings Per Share | -0.27 | -0.16 | -0.56 | -0.88 | -1.95 | -2.07 | -1.54 | -1.75 | -3.50 | -3.92 |
| Operating Cash Flow | 5.83 | -11.60 | -25.99 | -39.17 | -39.59 | -36.02 | -28.25 | -20.93 | -35.88 | -26.46 |
| Capital Expenditures | -3.81 | 4.54 | -0.79 | -3.63 | -8.88 | -9.05 | -0.76 | -0.85 | -1.55 | -0.91 |
| Free Cash Flow | 2.02 | -7.05 | -26.79 | -42.80 | -48.47 | -45.07 | -29.01 | -21.78 | -37.43 | -27.37 |
| Cash & Equivalents | 36.61 | 33.50 | 43.42 | 47.95 | 62.01 | 68.00 | 77.49 | 35.20 | 18.03 | 23.08 |
| Total Debt | 26.85 | - | - | - | - | - | - | - | - | 1.32 |
| Net Cash / Debt | 9.76 | 33.50 | 43.42 | 47.95 | 62.01 | 68.00 | 77.49 | 35.20 | 18.03 | 21.75 |
| Assets | 108 | 78.40 | 95.76 | 118 | 109 | 97.46 | 90.55 | 45.06 | 28.26 | 34.77 |
| Liabilities | 65.72 | 25.33 | 40.02 | 64.53 | 58.97 | 38.43 | 22.85 | 21.30 | 18.78 | 19.35 |
| Book Value | 41.90 | 53.07 | 55.74 | 53.58 | 50.07 | 59.04 | 67.70 | 23.76 | 9.48 | 15.42 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Avid Bioservices, Inc. |
| Country |
United States |
| Employees |
222 |
| CEO |
Nicholas S. Green |
Stock Information
| Ticker Symbol |
CDMO |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: CDMO |
Description
Avid Bioservices, a contract development and manufacturing organization, provides process development and current good manufacturing practices (CGMP) clinical and commercial manufacturing services focused on biopharmaceutical drug substances derived from mammalian cell culture. It produces monoclonal antibodies and recombinant proteins; and offers services, including CGMP clinical and commercial drug substance manufacturing, purification, bulk packaging, release and stability testing, and regulatory submission and support. The company also provides various process development services, such as upstream and downstream development and optimization, analytical methods development, testing, and characterization. It serves biotechnology and pharmaceutical companies. Avid Bioservices, Inc. has a process development and manufacturing agreement with Oragenics, Inc. to develop coronavirus vaccine. The company was formerly known as Peregrine Pharmaceuticals, Inc. and changed its name to Avid Bioservices, Inc. in January 2018. Avid Bioservices, Inc. was founded in 1981 and is headquartered in Tustin, California.